Navigation Links
Surviving Healthcare Reform: How Biopharma Companies Can Come Out on Top

STAMFORD, Conn. and WESTON, Mass., Nov. 6 /PRNewswire/ -- Those biopharmaceutical companies that are able to incorporate innovative and flexible elements into their business models will be best positioned to survive healthcare reform and maintain attractive long-term returns, according to a white paper published today by Cowen Healthcare Royalty Partners, a global healthcare private equity firm, and Health Advances, a leading healthcare strategy firm.

The paper, "Maintaining Attractive Biopharma Returns in the Face of Healthcare Reform", examines key issues at the center of the debate including access to care, controlling costs, drug pricing and value-based healthcare. In addition to discussing the increased pressures biopharma companies face, including the restrictive use of branded drugs for large patient populations and follow-on biologics, the paper outlines new solutions companies can implement to achieve the same levels of return for its investments as it has in the past.

Some of the paper's key findings include:

  • Biopharma companies need to adapt their business models to maintain attractive ROIs such as exploring pay-for-performance relationships with stakeholders, cost-effective care solutions that align incentives, and investing in follow-on biologics and/or generics
  • Investing in pharmacoeconomic competencies and integrating these into clinical development will mitigate reimbursement risk
  • Investing in personalized healthcare and specifically biomarkers will be rewarded
  • Highly differentiated products addressing niche markets will be the least vulnerable even if stringent regulation is passed

Gregory B. Brown, M.D., Co-Founder and Managing Director of Cowen Royalty, commented, "Healthcare reform is a serious issue for biopharma companies who are already feeling pressure from patent expirations, fewer drug approvals and growing development costs. We partnered with Health Advances to bring a new and unique perspective on the healthcare debate especially as it relates to biopharma companies -- the developers of many of our future medicines."

To download a copy of the white paper visit

About Cowen Healthcare Royalty Partners:

Cowen Healthcare Royalty Partners is a global healthcare private equity firm that invests principally in commercial-stage biopharmaceutical and medical device companies and products, through the purchase of royalty interests. The investment team has over 100 years of healthcare related experience including principal investing, structured finance, healthcare industry senior management, Wall Street research and consulting, scientific and clinical experience. For more information, visit

About Health Advances:

Founded in 1992, Health Advances is a leading healthcare strategy firm advising clients in the biopharma, device and diagnostic sectors. Industry executives and investors rely on Health Advances to advise them on their most challenging commercial decisions. For more information regarding our consulting services, visit

Media Contact:

    Kellie Walsh

SOURCE Cowen Healthcare Royalty Partners

SOURCE Cowen Healthcare Royalty Partners
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Chemobrain -- the flip side of surviving cancer
2. More Women Surviving After Early Breast Cancer
3. Early Menstruation Lowers Odds of Surviving Ovarian Cancer
4. More Extreme Preemies Surviving
5. Spike TV Goes Into Production of Special Episode of Original Series Surviving Disaster Focused on the Swine Flu and Other Pandemics
6. Surviving lung cancer
7. National Coalition for Cancer Survivorship, UCLA, WellPoint, and Genentech Launch Initiative to Provide Coordinated Follow-Up Care for People Surviving Cancer
8. White patients benefit more than blacks in surviving surgical complications at teaching hospitals
9. White Patients Benefit More Than Blacks in Surviving Surgical Complications at Teaching Hospitals
10. Penn study: Chances of surviving cardiac arrest depend on where patients are treated
11. Surviving the Holidays After a Loved Ones Death: Economic Woes Add to Holiday Pressure for People Who Grieve
Post Your Comments:
(Date:12/1/2015)... ... December 02, 2015 , ... ... Gastrointestinal events and association with initiation of treatment for osteoporosis ”. , As ... of pharmacological treatment in patients diagnosed with osteoporosis. Based on a large US ...
(Date:12/1/2015)... , ... December 01, 2015 , ... According to an ... groups has filed a discrimination claim against the U.S. Department of Health and Human ... Affordable Care Act (ACA) plans are breaking the clause in the law prohibiting the ...
(Date:12/1/2015)... Houston, TX (PRWEB) , ... December 01, 2015 , ... ... owner of Vitenas Cosmetic Surgery, has been named by MedEsthetics magazine as the Best ... best of the best among the many elite aesthetic physicians honored by the industry ...
(Date:12/1/2015)... ... December 01, 2015 , ... December 1, 2015—Since ... improvements in scientific research and discoveries, leading us to better understand the disease’s ... to those affected by HIV/AIDS. Mediaplanet’s cross-platform edition of “World AIDS Day” provides ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... the United States. Podiatrists are well aware that psychology-based patient non-compliance (disobedience of ... often catastrophic contributors to diseases of the diabetic foot. The American Board ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)...  Athletic apparel company Tommie Copper , ... $1.35 million to settle Federal Trade Commission charges ... clothing would relieve severe and chronic pain and ... Tommie Copper,s proposed settlement with ... founder and chairman Thomas Kallish to ...
(Date:12/1/2015)... , 1 de diciembre de 2015 /PRNewswire/ ... para cuchillas de precisión, develó hoy un ... identidad de marca. El nuevo logo destaca ... y la ingeniería de productos con cuchillas ... ...
(Date:12/1/2015)... PUNE, India , December 1, 2015 ... to a new market research report "Nucleic Acid Labeling ... Techniques (PCR, Nick Translation, Random Primer, In Vitro Transcription, ... to 2020", published by MarketsandMarkets, The global market is ... USD 1,271.8 Million in 2015, growing at a CAGR ...
Breaking Medicine Technology: